Erenumab discontinuation in migraine patients: final results of the APOLLON study
Göbel H et. al; ePoster: EPO-248
Long-term efficacy and impact of erenumab treatment on quality of life of patients participating in the APOLLON study
Göbel H et. al; ePresentation: EPR-136
Real-world evidence on 24 months of erenumab treatment of migraine Patients in Switzerland: Long-term data from SQUARE
Schäfer E et. al; ePoster: EPV000
Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from the APPRAISE study
Gil-Gouveia R, et al; ePresentation: EPR-147
Final results from a real-world evidence study on the treatment of migraine patients with erenumab in Germany (SPECTRE)
Gaul C, et al; ePoster: EPR-036
Inpatient constipation in migraine patients prescribed preventive medications in a U.S. electronic health record database
Chomistek AK, et al; ePoster: EPV-496
Erenumab discontinuation in migraine patients: Interim analysis of the APOLLON study population
Ortler S, et al; ePoster: EPV-498
2021 Presentations
Consistent efficacy and safety of erenumab in episodic migraine patients during a 5-year, open-label extension study
Ashina M, et al; Oral presentation: OPR-136
Erenumab versus topiramate for the prevention of migraine: results of a randomized active-controlled double-dummy trial (HER-MES)
Uwe Reuter, et al; Oral presentation: OPR-200
Migraine-related healthcare resource utilisation and costs associated with migraine chronification: a panel-based chart review
Vo P, et al; ePresentation: EPR-152
The SQUARE study population: patient characteristics of erenumab-treated patients in a real-world setting in Switzerland
Schäfer E, et al. ePoster: EPO-264
Cost offsets for erenumab responders regarding migraine-related healthcare resource use and productivity loss in Portugal
Silva C, et al; ePoster: EPO-274
Efficacy and safety of erenumab in Indian episodic migraine population: India subanalysis of Global EMPOwER study
Chowdhury D, et al; ePoster: EPO-420
The effect of erenumab on sick leave days and healthcare visits in patients with migraine in Finland
Nissilä M, et al; ePoster: EPO-732
Impact of erenumab in a Scandinavian chronic migraine population – an interim analysis of the IMPROVE phase IV trial
Amin FM et al; ePoster: EPO-735
2020 Presentations
Cardiovascular safety of erenumab in patients with migraine with or without a history of aura
Ashina, M. (2020). Cardiovascular safety of erenumab in patients with migraine with or without a history of aura. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 12
Oral presentation: O1016
Characteristics of the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine
Ehrlich, M. (2020). Characteristics of the first head-to-head, randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 13
Oral presentation: O1017
Characterisation of prescription patterns in episodic and chronic migraine patients starting treatment in a real life setting with erenumab in Germany (SPECTRE) – A Real world evidence study
Gaul, C. (2020). Characterisation of prescription patterns in episodic and chronic migraine patients starting treatment in a real life setting with erenumab in Germany (SPECTRE) – A Real world evidence study. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 154
ePresentation: EPR1088
Real-world trends in characteristics of migraine patients newly initiated on erenumab in the United States
Fang, J. (2020). Real-world Trends in Characteristics of Migraine Patients Newly Initiated on Erenumab in the United States. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 159
ePresentation: EPR1098
First data collection on the use of prophylactic migraine treatments including the monoclonal antibody erenumab focused on the patient’s personal experience (PERISCOPE)
Gaul, C. (2020). First data collection on the use of prophylactic migraine treatments including the monoclonal antibody Erenumab focused on the patient’s personal experience. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 161
ePresentation: EPR1101
The importance of considering the patient’s and treating physician’s view to generate comprehensive and unbiased real-world evidence data (PERISCOPE AND TELESCOPE)
Schuh, K. (2020). The importance of considering the patient’s and treating physician’s view to generate comprehensive and unbiased real-world evidence data. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 296
ePresentation: EPR2067
Analysis of the patient population for the assessment of long-term safety and tolerability of the monoclonal antibody erenumab and the frequency of drug holidays in the German treatment algorithm (APOLLON)
Göbel, H. (2020). Analysis of the patient population for the assessment of long-term safety and tolerability of the monoclonal antibody Erenumab and the frequency of drug holidays in the German treatment algorithm. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 296
ePresentation: EPR2068
Patient-reported outcomes in patients with migraine and prior prophylactic treatment failure: A subgroup analysis from the BECOME study
Pozo-Rosich, P. (2020). Patient-Reported Outcomes in Patients with Migraine and Prior Prophylactic Treatment Failure: A Subgroup Analysis from the BECOME Study. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 304
ePresentation: EPR2081
Impact of an employer-provided migraine coaching program on patient burden and engagement
Schaetz, L. (2020). Impact of an Employer-Provided Migraine Coaching Program on Patient Burden and Engagement. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 306
ePresentation: EPR2083
The burden of migraine in the Netherlands: results from the My Migraine Voice survey
Mos, E. (2020). The burden of migraine in the Netherlands: results from the My Migraine Voice Survey. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 866
ePoster: EPO2164
Real-world evidence data characterising the use of the monoclonal antibody erenumab in daily clinical routine in Germany from the treating physician’s perspective (TELESCOPE)
Koch, M. (2020). Real-world evidence data characterizing the use of the monoclonal antibody Erenumab in daily clinical routine in Germany from the treating physician’s perspective. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 442
ePresentation: EPR3045
Changes in acute migraine-specific medications after initiating erenumab: Results from a real-world retrospective cohort study in the United States
Hines, D. (2020). Changes in Acute Migraine-Specific Medications after Initiating Erenumab: Results from a Real-World Retrospective Cohort Study in the United States. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 443
ePresentation: EPR3047
Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment
Starling, A.J. (2020). Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-Care Acute Treatment. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 446
ePresentation: EPR3052
Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-Year interim results of the LIBERTY open-label extension study
Reuter, U. (2020). Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-year in-terim results of the LIBERTY open-label extension study. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 1298
ePoster: EPO5039
